Results 71 to 80 of about 691,317 (169)

Stress induces analgesia via orexin 1 receptor-initiated endocannabinoid/CB1 signaling in the mouse periaqueductal gray

open access: yes, 2017
The orexin system consists of orexin A/hypocretin 1 and orexin B/hypocretin 2, and OX1 and OX2 receptors. Our previous electrophysiological study showed that orexin A in the rat ventrolateral periaqueductal gray (vlPAG) induced antinociception via an OX1
邱麗珠   +1 more
core   +1 more source

Ageing‐related modification of sleep and breathing in orexin‐knockout narcoleptic mice

open access: yesJournal of Sleep Research, Volume 34, Issue 2, April 2025.
Summary Narcolepsy type‐1 (NT1) is a lifelong sleep disease, characterised by impairment of the orexinergic system, with a typical onset during adolescence and young adulthood. Since the wake–sleep cycle physiologically changes with ageing, this study aims to compare sleep patterns between orexin‐knockout (KO) and wild type (WT) control mice at ...
Stefano Bastianini   +7 more
wiley   +1 more source

Parasomnias and sleep‐related movement disorders induced by drugs in the adult population: a review about iatrogenic medication effects

open access: yesJournal of Sleep Research, Volume 34, Issue 2, April 2025.
Summary Parasomnias and sleep‐related movement disorders (SRMD) are major causes of sleep disorders and may be drug induced. The objective of this study was to conduct a systematic review of the literature to examine the association between drug use and the occurrence of parasomnias and SRMD.
Sylvain Dumont   +5 more
wiley   +1 more source

Orexin A induces bidirectional modulation of synaptic plasticity: Inhibiting long-term potentiation and preventing depotentiation

open access: yes, 2017
The orexin system consists of two peptides, orexin A and B and two receptors, OX1R and OX2R. It is implicated in learning and memory regulation while controversy remains on its role in modulating hippocampal synaptic plasticity in vivo and in vitro. Here,
Lu, Guan-Ling;Lee, Chia-Hsu;Chiou, Lih-Chu   +1 more
core   +1 more source

Respiratory safety of lemborexant in adult and elderly subjects with moderate‐to‐severe chronic obstructive pulmonary disease

open access: yesJournal of Sleep Research, Volume 34, Issue 2, April 2025.
Lemborexant 10 mg, a dual orexin‐receptor antagonist (DORA), did not elicit respiratory depressant effects, as measured by peripheral oxygen saturation (SpO2) or apnea–hypopnea index (AHI), in subjects with moderate‐to‐severe chronic obstructive pulmonary disease (COPD).
Jocelyn Y. Cheng   +3 more
wiley   +1 more source

The role of spinal orexin-1 receptors in posterior hypothalamic modulation of neuropathic pain.

open access: yes, 2007
The role of spinal orexin-1 receptors in posterior hypothalamic modulation of neuropathic ...
Younhee. Jeong (7985624)
core   +5 more sources

Targeting Orexin 2 Receptors in Idiopathic Hypersomnia and Narcolepsy: A Randomised Phase 1b Proof‐Of‐Concept Study of Alixorexton

open access: yesJournal of Sleep Research, EarlyView.
Orexin 2 receptor agonists have demonstrated that targeting the orexin system may address symptoms of central disorders of hypersomnolence. Results of this phase 1 study support the phase 2 clinical evaluation of oral alixorexton in patients with IH, NT2 and NT1.
Ronald R. Grunstein   +10 more
wiley   +1 more source

Daridorexant‐ Case Report of Possible Side‐Effect in Rare Mitochondrial Disorder

open access: yesJournal of Sleep Research, EarlyView.
ABSTRACT This case report describes a 40‐year‐old woman with maternally inherited diabetes and deafness (MIDD), a rare mitochondrial disorder, who received treatment with daridorexant due to severe chronic insomnia. She developed progression of her MIDD symptoms during treatment.
Sven Svedmyr, Joel Bergqvist
wiley   +1 more source

Orexin receptor expression in human adipose tissue: effects of orexin-A and orexin-B

open access: yes, 2006
Orexin-A and orexin-B, via their receptors orexin-1 receptor (OX1R) and orexin-2 receptor (OX2R) have been shown to play a role in the regulation of feeding, body weight, and energy expenditure.
Lehnert, H.   +11 more
core   +1 more source

Real‐World Status of Augmentation Therapy With Atypical Antipsychotics in Major Depressive Disorder: A Claims Database Study

open access: yesNeuropsychopharmacology Reports, Volume 46, Issue 4, December 2026.
Using real‐world data, AAP augmentation patterns were evaluated in patients with MDD initially treated with antidepressant monotherapy. AAP augmentation therapy was initiated after a relatively long interval. Although only a small proportion of patients received this therapy, nearly half showed claims‐defined continuation for more than 6 months ...
Hikaru Hori   +8 more
wiley   +1 more source

Home - About - Disclaimer - Privacy